StreetAlpha
13F holdings · Q3 2026

DAFNA Capital Management

Los Angeles, CA · files as DAFNA Capital Management LLC
Know the moment DAFNA Capital Management filesYou follow DAFNA Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1389933

DAFNA Capital Management reported 87 stocks worth $468M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (21.4%), ATRC (6.3%) and CMPS (5.7%). Compared with Q2 2026, the fund opened new positions in BBOT, PYXS and QNRX, added to CMPS, NKTR and DNLI, trimmed RVMD, ATRC and XBI and sold out of MBX, ARTV and OBIO.

Latest filing: what DAFNA Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
4 new17 added32 trimmed5 sold outBought about $16.1M · sold about $50.1M
New 4
Added 17
See all 17 →
Trimmed 32
  • RVMD−$15.5M−13%
  • XBI−$7.1M−23%
  • IBB−$6.5M−73%
  • ATRC−$4.2M−13%
  • Cybin Inc−$4.2M−66%
See all 32 →
Sold out 5

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$468M−10.7% vs last quarter
Stocks held874 new · 5 sold out
Top 5 weight42.6%fairly concentrated
Turnover14%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
RVMD
Revolution Medicines Inc
$100M21.4%487K−76K (−13%)8 of 8
2
ATRC
Atricure Inc
$29.4M6.3%523K−75K (−13%)8 of 8
3
CMPS
Compass Pathways PLC
$26.6M5.7%2.1M+124K (+6%)8 of 8
4
XBI
Spdr Series Trust
$23.9M5.1%152K−45K (−23%)8 of 8
5
NKTR
Nektar Therapeutics
$19.6M4.2%323K+5,000 (+2%)6 of 8
6
IDYA
Ideaya Biosciences Inc
$16.9M3.6%439K−59K (−12%)8 of 8
7
STXS
Stereotaxis Inc
$16.8M3.6%13.7MNo change8 of 8
8
DNLI
Denali Therapeutics Inc
$15.4M3.3%744K+5,000 (+1%)7 of 8
9
ASND
Ascendis Pharma A/s
$11.4M2.4%50K+1,500 (+3%)2 of 8
10
RCUS
Arcus Biosciences Inc
$11.4M2.4%440K−2,000 (−0%)8 of 8
🔒 77 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
MBX
Mbx Biosciences Inc
$652K12K
ARTV
Artiva Biotherapeutics Inc
$651K67K
OBIO
Orchestra Biomed Hldgs Inc
$547K127K
NVCT
Nuvectis Pharma Inc
$368K20K
BCYC
Bicycle Therapeutics PLC
$273K64K

Reported value

last 8 quarters
$389MQ4 '24
$348MQ1 '25
$357MQ2 '25
$399MQ3 '25
$425MQ4 '25
$434MQ1 '26
$524MQ2 '26
$468MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

DAFNA Capital Management 13F FAQ

What does DAFNA Capital Management own?

DAFNA Capital Management reported 87 stocks worth $468M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (21.4%), ATRC (6.3%) and CMPS (5.7%). The table above lists every position in the filing (the top 10 without an account).

What did DAFNA Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 4 new positions, 17 added to, 32 trimmed and 5 sold out. New positions include BBOT, PYXS and QNRX. It sold all of MBX, ARTV and OBIO.

When will DAFNA Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is DAFNA Capital Management's portfolio worth?

The Q3 2026 filing reports $468M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.